Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. 

As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. 

Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. 

Servier Indonesia was established in 1987 under PT Parvico Bersaudara and legally founded as PT Servier Indonesia in 2005. We are focusing on 3 therapeutic areas: Oncology, Neurology, Cardiometabolism & Venous Disease.

Further information, please visit www.servier.co.id

To report a suspected adverse event with a Servier drug, please visit www.servier.co.id

Servier Indonesia

Org chart

Teams

Offices